Pre-Exposure Prophylaxis Study of Lenacapavir and Emtricitabine/Tenofovir Alafenamide in Adolescent Girls and Young Women at Risk of HIV Infection

NCT04994509 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

5368

Enrollment

INDUSTRY

Sponsor class

Conditions

Pre-Exposure Prophylaxis of HIV Infection

Interventions

DRUG: Oral Lenacapavir (LEN)
DRUG: Subcutaneous (SC) Lenacapavir (LEN)
DRUG: F/TAF
DRUG: F/TDF
DRUG: Placebo SC LEN
DRUG: PTM Oral LEN
DRUG: PTM F/TAF
DRUG: PTM F/TDF

Sponsor

Gilead Sciences